Bowen Hanes & Co. Inc. Sells 372,455 Shares of Boston Scientific Corporation $BSX

Bowen Hanes & Co. Inc. cut its position in Boston Scientific Corporation (NYSE:BSX) by 89.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,825 shares of the medical equipment provider’s stock after selling 372,455 shares during the period. Bowen Hanes & Co. Inc.’s holdings in Boston Scientific were worth $4,083,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Journey Advisory Group LLC raised its holdings in Boston Scientific by 13.5% in the 3rd quarter. Journey Advisory Group LLC now owns 8,400 shares of the medical equipment provider’s stock worth $820,000 after acquiring an additional 1,000 shares during the last quarter. Personal CFO Solutions LLC increased its holdings in shares of Boston Scientific by 210.6% in the 3rd quarter. Personal CFO Solutions LLC now owns 8,675 shares of the medical equipment provider’s stock worth $847,000 after purchasing an additional 5,882 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new position in shares of Boston Scientific in the third quarter worth $257,000. Tredje AP fonden lifted its holdings in shares of Boston Scientific by 24.4% during the third quarter. Tredje AP fonden now owns 1,070,688 shares of the medical equipment provider’s stock valued at $104,531,000 after purchasing an additional 210,000 shares in the last quarter. Finally, Stevens Capital Management LP boosted its position in shares of Boston Scientific by 103.6% during the third quarter. Stevens Capital Management LP now owns 72,296 shares of the medical equipment provider’s stock valued at $7,058,000 after buying an additional 36,784 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Down 1.6%

Shares of Boston Scientific stock opened at $74.54 on Friday. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50. The company’s fifty day simple moving average is $89.23 and its 200-day simple moving average is $96.57. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 0.96. The stock has a market capitalization of $110.61 billion, a PE ratio of 38.42, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. National Bank Financial set a $115.00 target price on Boston Scientific in a research report on Monday, February 2nd. JPMorgan Chase & Co. decreased their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday. UBS Group cut their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.